Clinical Scorecard: Is gene editing the potential single-treatment solution for high cholesterol?

At a Glance

Key Highlights

• Early-stage gene-editing studies show a single infusion can reduce LDL cholesterol and triglycerides by about 50%.
• Gene editing targets genes ANGPTL3 and PCSK9, naturally associated with very low cholesterol in some individuals.
• Long-term safety and efficacy remain unknown; gene editing is considered permanent but requires further large-scale studies.

Guideline-Based Recommendations

Diagnosis

• Assess LDL cholesterol levels to identify high-risk individuals.
• Consider genetic factors influencing cholesterol metabolism.

Management

• Lifestyle modifications: heart-healthy diet, physical activity, weight management, smoking cessation, adequate sleep.
• Pharmacologic treatments: statins as first-line therapy; other pills or injected medicines if statins insufficient or not tolerated.
• Gene-editing therapies currently experimental and limited to clinical trials for high-risk patients.

Monitoring & Follow-up

• Regular lipid profile monitoring to assess LDL and triglyceride levels.
• Monitor liver function and potential side effects during gene-editing trials.
• Long-term follow-up needed for gene-editing recipients to evaluate durability and safety.

Risks

• Potential liver irritation or inflammation from gene-editing delivery particles.
• Unknown long-term safety and off-target gene-editing effects.
• Challenges in adherence to lifelong cholesterol-lowering medications.

Patient & Prescribing Data

Adults with high LDL cholesterol at high risk for cardiovascular disease, including those with genetic predispositions

Gene-editing treatments have shown promising LDL and triglyceride reductions in small early trials; currently investigational and not widely available.

Clinical Best Practices

• Prioritize lifestyle interventions and established pharmacologic therapies for cholesterol management.
• Consider gene-editing therapies only within controlled clinical trials for eligible high-risk patients.
• Educate patients on the importance of adherence to current cholesterol-lowering treatments and lifestyle changes.
• Monitor patients closely for side effects and efficacy when using novel gene-editing approaches.

References

• New England Journal of Medicine study on ANGPTL3 gene editing
• American Heart Association cholesterol guidelines
• CRISPR Therapeutics and Verve Therapeutics gene-editing trials